« Back
Home /
DLK-IN-1

DLK-IN-1

Item no.	HY-114331-50mg
Manufacturer	MedChem Express
CASRN	1620574-24-4
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.18
Citations	[1]Patel S, et al. Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease. J Med Chem. 2017 Oct 12;60(19):8083-8102.
Smiles	CC(N1C([C@@H]2[C@]3([H])[C@@]2([H])CN(C4COC4)C3)=CC(C5=CN=C(N)C(OC(F)(F)F)=C5)=N1)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1620574-24-4
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neurodegeneration
Manufacturer - Targets	FLT3; MAP3K; PAK; STK33; Trk Receptor
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	423.43
Product Description	DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research[1].
Manufacturer - Research Area	Neurological Disease
Solubility	DMSO: 62.5 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Neuronal Signaling; Protein Tyrosine Kinase/RTK
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-114331-50mg-safety-datasheet.pdf